source
- FDA requests public input to accelerate botanical drug product developmentThe U.S. Food and Drug Administration issued a request for information (RFI) to collect public comments on ways to move botanical drug products forward. Botanical drug products are derived from pl…
- GSK pays $110 million upfront for exclusive rights to HUTCHMED’s dual-target cancer therapy HMPL-A830GSK announced a partnership with Hong Kong-based HUTCHMED, paying $110 million upfront for exclusive global rights to develop HMPL-A830. HMPL-A830 is an investigational antibody-targeted therapy c…